Platinol and Erbitux drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Platinol (cisplatin) and Erbitux (cetuximab). Common drug interactions include death among females and malignant neoplasm progression among males.

The phase IV clinical study analyzes what interactions people have when they take Platinol and Erbitux. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Platinol?

Platinol has active ingredients of cisplatin. eHealthMe is studying from 1,249 Platinol users. Check the latest studies of Platinol.

What is Erbitux?

Erbitux has active ingredients of cetuximab. It is often used in cancer. eHealthMe is studying from 19,276 Erbitux users. Check the latest studies of Erbitux.

On Jul, 27, 2026

11 people who take Platinol and Erbitux together, and have interactions are studied.

What are the common drug interactions of Platinol and Erbitux, by gender? *:

female:

Death

male:

Malignant neoplasm progression (cancer tumour came back)
Hypokalaemia (low potassium)
Diarrhoea
Dyspnoea (difficult or laboured respiration)
Failure to thrive (inadequate weight gain and physical growth in children)
Flushing (the warm, red condition of human skin)
Gastritis haemorrhagic (inflammation of stomach with bleeding)
Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
Heart rate increased
Hypotension (abnormally low blood pressure)

What are the common drug interactions of Platinol and Erbitux, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Mouth ulceration (mouth ulcers)
Myelosuppression (a decrease in the production of blood cells)
Respiratory failure (inadequate gas exchange by the respiratory system)
Gastritis haemorrhagic (inflammation of stomach with bleeding)
Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
Hypotension (abnormally low blood pressure)
Malignant neoplasm progression (cancer tumour came back)
Oesophageal ulcer (ulcer of oesophagus)
Oxygen saturation decreased
Respiratory distress (difficulty in breathing)

60+:

Dehydration (dryness resulting from the removal of water)
Diarrhoea
Failure to thrive (inadequate weight gain and physical growth in children)
Malignant neoplasm progression (cancer tumour came back)
Neutropenia (an abnormally low number of neutrophils)
Skin cancer

What are the existing conditions these people have? *

Neoplasm Malignant (cancer tumour): 2 people, 18.18%
Oral Cancer (mouth cancer): 1 person, 9.09%
Metastatic Squamous Cell Carcinoma (cancer of squamous cells spreads to other part): 1 person, 9.09%
Lung Cancer - Non-Small Cell (lung cancer): 1 person, 9.09%
Laryngeal Cancer Recurrent (repeat cancer of the larynx): 1 person, 9.09%
Gallbladder Cancer: 1 person, 9.09%
Coronary Heart Disease (narrowing or blockage of the coronary arteries): 1 person, 9.09%
Colon Cancer Metastatic (cancer of colon spreads to other part of body): 1 person, 9.09%
Cholangiocarcinoma (a cancer that forms glands or secretes significant amounts of mucins): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Platinol and Erbitux?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously